Global MET Inhibitor Drugs Market

MET Inhibitor Drugs Comprehensive Study by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

MET Inhibitor Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About MET Inhibitor Drugs
MET inhibitor drugs are the group of drugs that inhibits the mutated forms of the MET gene that may cause abnormal cell growth and spread in the body. These drugs are primarily used for the treatment of different types of cancers such as breast, colon, and lung cancers. According to World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for about 10 million deaths per year. The factors such as the Increased Prevalence of Cancers among People Worldwide and High Demand for Alternative Treatments for Cancers are the drivers for the global MET Inhibitor Drugs market. In addition, Increased Research and Development Funding also fueling the market growth. However, Limitations Associated with MET Inhibitor Drugs may hinder the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global MET Inhibitor Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Johnson and Johnson (United States), Novartis International AG (Switzerland), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Takeda Pharmaceutical Company (Japan), GlaxoSmithKline plc (United Kingdom) and Amgen Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bristol Myers Squibb (United States), Daiichi Sankyo Company, Limited (Japan) and Others.

Segmentation Overview
AMA Research has segmented the market of Global MET Inhibitor Drugs market by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies and Kringle Variant Antagonists) and Region.



On the basis of geography, the market of MET Inhibitor Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Funding

Market Growth Drivers:
Increased Prevalence of Cancer among People Worldwide, High Demand for Alternative Treatments for Cancers and Growth in the Healthcare Infrastructure in Developing Countries

Challenges:
Stringent Government Rules and Regulations

Restraints:
Limitations Associated with MET Inhibitor Drugs

Opportunities:
Growth in the Healthcare Industry and Huge Investments by Major Players

Market Leaders and their expansionary development strategies
In February 2023, Acquired MET D1228H/N or D1246N mutations were found in patients harboring MET fusions after acquiring resistance to MET TKIs.
In May 2020, Novartis announced that the United States Food and Drug Administration (FDA) has approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test.


Key Target Audience
MET Inhibitor Drugs Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • C-Met Biological Inhibitors
  • Small Molecule C-Met Inhibitors
  • C-Met Antagonist Antibodies
  • HGF Antagonist Antibodies
  • Kringle Variant Antagonists
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancer among People Worldwide
      • 3.2.2. High Demand for Alternative Treatments for Cancers
      • 3.2.3. Growth in the Healthcare Infrastructure in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Funding
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global MET Inhibitor Drugs, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global MET Inhibitor Drugs (Value)
      • 5.2.1. Global MET Inhibitor Drugs by: Type (Value)
        • 5.2.1.1. C-Met Biological Inhibitors
        • 5.2.1.2. Small Molecule C-Met Inhibitors
        • 5.2.1.3. C-Met Antagonist Antibodies
        • 5.2.1.4. HGF Antagonist Antibodies
        • 5.2.1.5. Kringle Variant Antagonists
      • 5.2.2. Global MET Inhibitor Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Online Stores
      • 5.2.3. Global MET Inhibitor Drugs by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global MET Inhibitor Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global MET Inhibitor Drugs (Volume)
      • 5.3.1. Global MET Inhibitor Drugs by: Type (Volume)
        • 5.3.1.1. C-Met Biological Inhibitors
        • 5.3.1.2. Small Molecule C-Met Inhibitors
        • 5.3.1.3. C-Met Antagonist Antibodies
        • 5.3.1.4. HGF Antagonist Antibodies
        • 5.3.1.5. Kringle Variant Antagonists
      • 5.3.2. Global MET Inhibitor Drugs by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Retail Pharmacies
        • 5.3.2.3. Drug Stores
        • 5.3.2.4. Online Stores
      • 5.3.3. Global MET Inhibitor Drugs by: End-user (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global MET Inhibitor Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global MET Inhibitor Drugs (Price)
      • 5.4.1. Global MET Inhibitor Drugs by: Type (Price)
  • 6. MET Inhibitor Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson and Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global MET Inhibitor Drugs Sale, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global MET Inhibitor Drugs (Value)
      • 7.2.1. Global MET Inhibitor Drugs by: Type (Value)
        • 7.2.1.1. C-Met Biological Inhibitors
        • 7.2.1.2. Small Molecule C-Met Inhibitors
        • 7.2.1.3. C-Met Antagonist Antibodies
        • 7.2.1.4. HGF Antagonist Antibodies
        • 7.2.1.5. Kringle Variant Antagonists
      • 7.2.2. Global MET Inhibitor Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Online Stores
      • 7.2.3. Global MET Inhibitor Drugs by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global MET Inhibitor Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global MET Inhibitor Drugs (Volume)
      • 7.3.1. Global MET Inhibitor Drugs by: Type (Volume)
        • 7.3.1.1. C-Met Biological Inhibitors
        • 7.3.1.2. Small Molecule C-Met Inhibitors
        • 7.3.1.3. C-Met Antagonist Antibodies
        • 7.3.1.4. HGF Antagonist Antibodies
        • 7.3.1.5. Kringle Variant Antagonists
      • 7.3.2. Global MET Inhibitor Drugs by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Retail Pharmacies
        • 7.3.2.3. Drug Stores
        • 7.3.2.4. Online Stores
      • 7.3.3. Global MET Inhibitor Drugs by: End-user (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global MET Inhibitor Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global MET Inhibitor Drugs (Price)
      • 7.4.1. Global MET Inhibitor Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. MET Inhibitor Drugs: by Type(USD Million)
  • Table 2. MET Inhibitor Drugs C-Met Biological Inhibitors , by Region USD Million (2018-2023)
  • Table 3. MET Inhibitor Drugs Small Molecule C-Met Inhibitors , by Region USD Million (2018-2023)
  • Table 4. MET Inhibitor Drugs C-Met Antagonist Antibodies , by Region USD Million (2018-2023)
  • Table 5. MET Inhibitor Drugs HGF Antagonist Antibodies , by Region USD Million (2018-2023)
  • Table 6. MET Inhibitor Drugs Kringle Variant Antagonists , by Region USD Million (2018-2023)
  • Table 7. MET Inhibitor Drugs: by Distribution Channel(USD Million)
  • Table 8. MET Inhibitor Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 9. MET Inhibitor Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 10. MET Inhibitor Drugs Drug Stores , by Region USD Million (2018-2023)
  • Table 11. MET Inhibitor Drugs Online Stores , by Region USD Million (2018-2023)
  • Table 12. MET Inhibitor Drugs: by End-user(USD Million)
  • Table 13. MET Inhibitor Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 14. MET Inhibitor Drugs Clinics , by Region USD Million (2018-2023)
  • Table 15. MET Inhibitor Drugs Others , by Region USD Million (2018-2023)
  • Table 16. South America MET Inhibitor Drugs, by Country USD Million (2018-2023)
  • Table 17. South America MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 18. South America MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 19. South America MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 20. Brazil MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 21. Brazil MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 23. Argentina MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 24. Argentina MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Argentina MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 26. Rest of South America MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 27. Rest of South America MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 28. Rest of South America MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 29. Asia Pacific MET Inhibitor Drugs, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 32. Asia Pacific MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 33. China MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 34. China MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 35. China MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 36. Japan MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 37. Japan MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 38. Japan MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 39. India MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 40. India MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 41. India MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 42. South Korea MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 43. South Korea MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 44. South Korea MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 45. Taiwan MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 46. Taiwan MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. Taiwan MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 48. Australia MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 49. Australia MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. Australia MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 54. Europe MET Inhibitor Drugs, by Country USD Million (2018-2023)
  • Table 55. Europe MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 56. Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 57. Europe MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 58. Germany MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 59. Germany MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 60. Germany MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 61. France MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 62. France MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. France MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 64. Italy MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 65. Italy MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Italy MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 67. United Kingdom MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 68. United Kingdom MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 69. United Kingdom MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 70. Netherlands MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 71. Netherlands MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. Netherlands MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 73. Rest of Europe MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 75. Rest of Europe MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 76. MEA MET Inhibitor Drugs, by Country USD Million (2018-2023)
  • Table 77. MEA MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 78. MEA MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 79. MEA MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 80. Middle East MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 81. Middle East MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 82. Middle East MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 83. Africa MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 84. Africa MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 85. Africa MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 86. North America MET Inhibitor Drugs, by Country USD Million (2018-2023)
  • Table 87. North America MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 88. North America MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 89. North America MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 90. United States MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 91. United States MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. United States MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 93. Canada MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 94. Canada MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 95. Canada MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 96. Mexico MET Inhibitor Drugs, by Type USD Million (2018-2023)
  • Table 97. Mexico MET Inhibitor Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 98. Mexico MET Inhibitor Drugs, by End-user USD Million (2018-2023)
  • Table 99. MET Inhibitor Drugs Sales: by Type(K Units)
  • Table 100. MET Inhibitor Drugs Sales C-Met Biological Inhibitors , by Region K Units (2018-2023)
  • Table 101. MET Inhibitor Drugs Sales Small Molecule C-Met Inhibitors , by Region K Units (2018-2023)
  • Table 102. MET Inhibitor Drugs Sales C-Met Antagonist Antibodies , by Region K Units (2018-2023)
  • Table 103. MET Inhibitor Drugs Sales HGF Antagonist Antibodies , by Region K Units (2018-2023)
  • Table 104. MET Inhibitor Drugs Sales Kringle Variant Antagonists , by Region K Units (2018-2023)
  • Table 105. MET Inhibitor Drugs Sales: by Distribution Channel(K Units)
  • Table 106. MET Inhibitor Drugs Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 107. MET Inhibitor Drugs Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 108. MET Inhibitor Drugs Sales Drug Stores , by Region K Units (2018-2023)
  • Table 109. MET Inhibitor Drugs Sales Online Stores , by Region K Units (2018-2023)
  • Table 110. MET Inhibitor Drugs Sales: by End-user(K Units)
  • Table 111. MET Inhibitor Drugs Sales Hospitals , by Region K Units (2018-2023)
  • Table 112. MET Inhibitor Drugs Sales Clinics , by Region K Units (2018-2023)
  • Table 113. MET Inhibitor Drugs Sales Others , by Region K Units (2018-2023)
  • Table 114. South America MET Inhibitor Drugs Sales, by Country K Units (2018-2023)
  • Table 115. South America MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 116. South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 117. South America MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 118. Brazil MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 119. Brazil MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 120. Brazil MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 121. Argentina MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 122. Argentina MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 123. Argentina MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 124. Rest of South America MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 125. Rest of South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 126. Rest of South America MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 127. Asia Pacific MET Inhibitor Drugs Sales, by Country K Units (2018-2023)
  • Table 128. Asia Pacific MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 129. Asia Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 130. Asia Pacific MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 131. China MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 132. China MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 133. China MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 134. Japan MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 135. Japan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 136. Japan MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 137. India MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 138. India MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 139. India MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 140. South Korea MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 141. South Korea MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 142. South Korea MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 143. Taiwan MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 144. Taiwan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 145. Taiwan MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 146. Australia MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 147. Australia MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 148. Australia MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 149. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 150. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 151. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 152. Europe MET Inhibitor Drugs Sales, by Country K Units (2018-2023)
  • Table 153. Europe MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 154. Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 155. Europe MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 156. Germany MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 157. Germany MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 158. Germany MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 159. France MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 160. France MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 161. France MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 162. Italy MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 163. Italy MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 164. Italy MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 165. United Kingdom MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 166. United Kingdom MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 167. United Kingdom MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 168. Netherlands MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 169. Netherlands MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 170. Netherlands MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 171. Rest of Europe MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 172. Rest of Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 173. Rest of Europe MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 174. MEA MET Inhibitor Drugs Sales, by Country K Units (2018-2023)
  • Table 175. MEA MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 176. MEA MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 177. MEA MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 178. Middle East MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 179. Middle East MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 180. Middle East MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 181. Africa MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 182. Africa MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 183. Africa MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 184. North America MET Inhibitor Drugs Sales, by Country K Units (2018-2023)
  • Table 185. North America MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 186. North America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 187. North America MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 188. United States MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 189. United States MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 190. United States MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 191. Canada MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 192. Canada MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 193. Canada MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 194. Mexico MET Inhibitor Drugs Sales, by Type K Units (2018-2023)
  • Table 195. Mexico MET Inhibitor Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 196. Mexico MET Inhibitor Drugs Sales, by End-user K Units (2018-2023)
  • Table 197. MET Inhibitor Drugs: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. MET Inhibitor Drugs: by Type(USD Million)
  • Table 208. MET Inhibitor Drugs C-Met Biological Inhibitors , by Region USD Million (2025-2030)
  • Table 209. MET Inhibitor Drugs Small Molecule C-Met Inhibitors , by Region USD Million (2025-2030)
  • Table 210. MET Inhibitor Drugs C-Met Antagonist Antibodies , by Region USD Million (2025-2030)
  • Table 211. MET Inhibitor Drugs HGF Antagonist Antibodies , by Region USD Million (2025-2030)
  • Table 212. MET Inhibitor Drugs Kringle Variant Antagonists , by Region USD Million (2025-2030)
  • Table 213. MET Inhibitor Drugs: by Distribution Channel(USD Million)
  • Table 214. MET Inhibitor Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 215. MET Inhibitor Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 216. MET Inhibitor Drugs Drug Stores , by Region USD Million (2025-2030)
  • Table 217. MET Inhibitor Drugs Online Stores , by Region USD Million (2025-2030)
  • Table 218. MET Inhibitor Drugs: by End-user(USD Million)
  • Table 219. MET Inhibitor Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 220. MET Inhibitor Drugs Clinics , by Region USD Million (2025-2030)
  • Table 221. MET Inhibitor Drugs Others , by Region USD Million (2025-2030)
  • Table 222. South America MET Inhibitor Drugs, by Country USD Million (2025-2030)
  • Table 223. South America MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 224. South America MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 225. South America MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 226. Brazil MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 227. Brazil MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 228. Brazil MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 229. Argentina MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 230. Argentina MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 231. Argentina MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 232. Rest of South America MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 233. Rest of South America MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 234. Rest of South America MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 235. Asia Pacific MET Inhibitor Drugs, by Country USD Million (2025-2030)
  • Table 236. Asia Pacific MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 237. Asia Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 238. Asia Pacific MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 239. China MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 240. China MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 241. China MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 242. Japan MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 243. Japan MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 244. Japan MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 245. India MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 246. India MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 247. India MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 248. South Korea MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 249. South Korea MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 250. South Korea MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 251. Taiwan MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 252. Taiwan MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 253. Taiwan MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 254. Australia MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 255. Australia MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 256. Australia MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 257. Rest of Asia-Pacific MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 258. Rest of Asia-Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 260. Europe MET Inhibitor Drugs, by Country USD Million (2025-2030)
  • Table 261. Europe MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 262. Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 263. Europe MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 264. Germany MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 265. Germany MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 266. Germany MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 267. France MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 268. France MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 269. France MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 270. Italy MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 271. Italy MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 272. Italy MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 273. United Kingdom MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 274. United Kingdom MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 275. United Kingdom MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 276. Netherlands MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 277. Netherlands MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 278. Netherlands MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 279. Rest of Europe MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 280. Rest of Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 281. Rest of Europe MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 282. MEA MET Inhibitor Drugs, by Country USD Million (2025-2030)
  • Table 283. MEA MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 284. MEA MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 285. MEA MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 286. Middle East MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 287. Middle East MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 288. Middle East MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 289. Africa MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 290. Africa MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 291. Africa MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 292. North America MET Inhibitor Drugs, by Country USD Million (2025-2030)
  • Table 293. North America MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 294. North America MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 295. North America MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 296. United States MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 297. United States MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 298. United States MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 299. Canada MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 300. Canada MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 301. Canada MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 302. Mexico MET Inhibitor Drugs, by Type USD Million (2025-2030)
  • Table 303. Mexico MET Inhibitor Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 304. Mexico MET Inhibitor Drugs, by End-user USD Million (2025-2030)
  • Table 305. MET Inhibitor Drugs Sales: by Type(K Units)
  • Table 306. MET Inhibitor Drugs Sales C-Met Biological Inhibitors , by Region K Units (2025-2030)
  • Table 307. MET Inhibitor Drugs Sales Small Molecule C-Met Inhibitors , by Region K Units (2025-2030)
  • Table 308. MET Inhibitor Drugs Sales C-Met Antagonist Antibodies , by Region K Units (2025-2030)
  • Table 309. MET Inhibitor Drugs Sales HGF Antagonist Antibodies , by Region K Units (2025-2030)
  • Table 310. MET Inhibitor Drugs Sales Kringle Variant Antagonists , by Region K Units (2025-2030)
  • Table 311. MET Inhibitor Drugs Sales: by Distribution Channel(K Units)
  • Table 312. MET Inhibitor Drugs Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 313. MET Inhibitor Drugs Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 314. MET Inhibitor Drugs Sales Drug Stores , by Region K Units (2025-2030)
  • Table 315. MET Inhibitor Drugs Sales Online Stores , by Region K Units (2025-2030)
  • Table 316. MET Inhibitor Drugs Sales: by End-user(K Units)
  • Table 317. MET Inhibitor Drugs Sales Hospitals , by Region K Units (2025-2030)
  • Table 318. MET Inhibitor Drugs Sales Clinics , by Region K Units (2025-2030)
  • Table 319. MET Inhibitor Drugs Sales Others , by Region K Units (2025-2030)
  • Table 320. South America MET Inhibitor Drugs Sales, by Country K Units (2025-2030)
  • Table 321. South America MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 322. South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 323. South America MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 324. Brazil MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 325. Brazil MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 326. Brazil MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 327. Argentina MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 328. Argentina MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 329. Argentina MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 330. Rest of South America MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 331. Rest of South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 332. Rest of South America MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 333. Asia Pacific MET Inhibitor Drugs Sales, by Country K Units (2025-2030)
  • Table 334. Asia Pacific MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 335. Asia Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 336. Asia Pacific MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 337. China MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 338. China MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 339. China MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 340. Japan MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 341. Japan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 342. Japan MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 343. India MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 344. India MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 345. India MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 346. South Korea MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 347. South Korea MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 348. South Korea MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 349. Taiwan MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 350. Taiwan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 351. Taiwan MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 352. Australia MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 353. Australia MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 354. Australia MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 355. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 356. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 357. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 358. Europe MET Inhibitor Drugs Sales, by Country K Units (2025-2030)
  • Table 359. Europe MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 360. Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 361. Europe MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 362. Germany MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 363. Germany MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 364. Germany MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 365. France MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 366. France MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 367. France MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 368. Italy MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 369. Italy MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 370. Italy MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 371. United Kingdom MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 372. United Kingdom MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 373. United Kingdom MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 374. Netherlands MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 375. Netherlands MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 376. Netherlands MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 377. Rest of Europe MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 378. Rest of Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 379. Rest of Europe MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 380. MEA MET Inhibitor Drugs Sales, by Country K Units (2025-2030)
  • Table 381. MEA MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 382. MEA MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 383. MEA MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 384. Middle East MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 385. Middle East MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 386. Middle East MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 387. Africa MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 388. Africa MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 389. Africa MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 390. North America MET Inhibitor Drugs Sales, by Country K Units (2025-2030)
  • Table 391. North America MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 392. North America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 393. North America MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 394. United States MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 395. United States MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 396. United States MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 397. Canada MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 398. Canada MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 399. Canada MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 400. Mexico MET Inhibitor Drugs Sales, by Type K Units (2025-2030)
  • Table 401. Mexico MET Inhibitor Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 402. Mexico MET Inhibitor Drugs Sales, by End-user K Units (2025-2030)
  • Table 403. MET Inhibitor Drugs: by Type(USD/Units)
  • Table 404. Research Programs/Design for This Report
  • Table 405. Key Data Information from Secondary Sources
  • Table 406. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global MET Inhibitor Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global MET Inhibitor Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global MET Inhibitor Drugs: by End-user USD Million (2018-2023)
  • Figure 7. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 8. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 9. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 10. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 11. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 12. Global MET Inhibitor Drugs: by Type K Units (2018-2023)
  • Figure 13. Global MET Inhibitor Drugs: by Distribution Channel K Units (2018-2023)
  • Figure 14. Global MET Inhibitor Drugs: by End-user K Units (2018-2023)
  • Figure 15. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 16. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 17. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 18. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 19. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 20. Global MET Inhibitor Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Global MET Inhibitor Drugs share by Players 2023 (%)
  • Figure 22. Global MET Inhibitor Drugs share by Players (Top 3) 2023(%)
  • Figure 23. Global MET Inhibitor Drugs share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 27. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2023
  • Figure 39. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Global MET Inhibitor Drugs: by Type USD Million (2025-2030)
  • Figure 44. Global MET Inhibitor Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 45. Global MET Inhibitor Drugs: by End-user USD Million (2025-2030)
  • Figure 46. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 47. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 48. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 49. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 50. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 51. Global MET Inhibitor Drugs: by Type K Units (2025-2030)
  • Figure 52. Global MET Inhibitor Drugs: by Distribution Channel K Units (2025-2030)
  • Figure 53. Global MET Inhibitor Drugs: by End-user K Units (2025-2030)
  • Figure 54. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 55. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 56. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 57. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 58. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 59. Global MET Inhibitor Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Johnson and Johnson (United States)
  • Novartis International AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Pfizer Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Takeda Pharmaceutical Company (Japan)
  • GlaxoSmithKline plc (United Kingdom)
  • Amgen Inc. (United States)
Additional players considered in the study are as follows:
Bristol Myers Squibb (United States) , Daiichi Sankyo Company, Limited (Japan) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 230 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global MET Inhibitor Drugs Market Quantitative research analysis
Global MET Inhibitor Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Johnson and Johnson (United States), Novartis International AG (Switzerland), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Takeda Pharmaceutical Company (Japan), GlaxoSmithKline plc (United Kingdom) and Amgen Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Research and Development Funding" is seen as one of major influencing trends for MET Inhibitor Drugs Market during projected period 2023-2030.
The MET Inhibitor Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global MET Inhibitor Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Kennel Cough Treatment Comprehensive Study by Application (Mild Cases, Secondary Infection), Drug Type (Baytril, Doxycycline, Clavamox, Others), Route of Administration (Oral, Injectable, Intra-nasal...
$ 3450
Antiviral Drugs Treatment Comprehensive Study by Type (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators), Application (Hepatitis, HIV/AIDS, Herpes, I...
$ 3500
Fish Free Omega 3 Comprehensive Study by Type (Alpha-Linolenic Acid (ALA), Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)), Application (Dietary Supplements, Pharma and Personal, Animal Feed...
$ 3750
Triamterene Tablets Comprehensive Study by Application (Hospital, Retail Pharmacies, Other), End Use (Metabolic or Respiratory Acidosis, Acute Myopia & Secondary Angle-Closure Glaucoma), Packaging (B...
$ 3350
Propyl Thiouracil Comprehensive Study by Mechanism of Action (Thyroperoxidase Inhibitor, 5- deiodinase Inhibitor), Distribution Channel (Hospitals, Pharmacies), End User (Adult, Children) Players and...
$ 3500
Ophthalmic Dye Comprehensive Study by Application (Ophthalmic Diagnosis, Ophthalmic Surgery), Drug (Fluorescein Dye, Rose Bengal Stain, Trypan Blue, Others), Distribution Channel (Hospital Pharmacies...
$ 3500